

available at www.sciencedirect.comjournal homepage: euoncology.europeanurology.com

European Association of Urology



A Comprehensive National Survey of Prostate-specific Antigen Testing and Prostate Cancer Management in France: Uncovering Regional and Temporal Disparities

Olivier Cussenot^{a,b,*}, Yoann Taille^c, Jean-Jacques Portal^c, Géraldine Cancel-Tassin^{b,d}, Morgan Roupret^{b,d}, Alexandre de la Taille^e, Guillaume Ploussard^f, Romain Mathieu^g, Freddie C. Hamdy^a, Eric Vicaut^c

^a Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK; ^b CeRePP, Paris, France; ^c Clinical Research Unit, AP-HP. Nord - University Paris Cité, Paris, France; ^d GRC n°5 Predictive Onco-Urology, AP-HP, Sorbonne Université, Paris, France; ^e Department of Urology, AP-HP, Hôpitaux Universitaires Henri Mondor, University of Creteil, Créteil, France; ^f Department of Urology, La Croix du Sud Hospital, Quint Fonsegrives, France; ^g Department of Urology, CHU Rennes, Rennes, France

Article info

Article history:

Received 24 January 2024

Accepted February 26, 2024

Keywords:

Management
Mortality
Prostate cancer
Prostate-specific antigen
Real-life data

Abstract

We report nationwide real-life practice in the management of prostate cancer (PC) in France in a population of 4 936 750 men. All prostate-specific antigen (PSA) blood tests performed between 2006 and 2018 were recorded in a National Health registry, which allowed to identify 692 516 men diagnosed with PC and a control population consisting of 3 899 509 men without PC. PSA tests, age at diagnosis, treatments, and survival were analysed. Their management was analysed by age range and compared in the different French regions. Disparities were found in age at PSA testing and management approaches (surveillance, and local and systemic therapies). We found that 50% of men had received five PSA blood tests, but the first PSA test was taken late in life, with a peak in the decade between 65 and 75 yr of age. Adoption of monitoring was low (12%). Older men appeared to receive a late diagnosis with reduced chances of curative therapy and a subsequent increase in mortality, but cautious interpretation of our data is warranted in view of competing morbidities and other causes of death. The incidence of metastases at diagnosis, indicated by the use of systemic therapies, increased progressively from 2011 onwards.

Patient summary: In this study, we report nationwide real-life practice in the management of prostate cancer (PC) in France in a population of 4 936 750 men, including 692 516 patients with PC. We found that the first prostate-specific antigen test is taken too late in life, leading to a late diagnosis with reduced chances of curative therapy and a subsequent increase in mortality.

© 2024 European Association of Urology. Published by Elsevier B.V. All rights reserved.

* Corresponding author. Nuffield Department of Surgical Sciences, University of Oxford, Old Road Campus Research Building (off Roosevelt Drive) Headington, Oxford OX3 7DQ, UK. Tel. +33 1 56 01 76 46; Fax: +33 1 56 01 76 47.

E-mail address: o.cussenot@cerepp.org (O. Cussenot).

<https://doi.org/10.1016/j.euo.2024.02.008>

2588-9311/© 2024 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Prostate cancer (PC) is a leading cause of cancer-related deaths in Europe, with a standardised death rate of approximately 37.4 per 100 000 male residents of the European Union in 2019 [1]. The management of PC, including the use of prostate-specific antigen (PSA) testing for early detection and initial therapeutic strategies, remains controversial [2]. Although health care authorities and professional societies have provided guidelines to reduce the harms associated with PSA testing in primary care, metastatic disease continues to be diagnosed at an increasing rate [3], despite a paradoxical decline in disease-specific mortality in recent years. Furthermore, there are still significant regional disparities in the incidence of PC and disease-specific mortality, which may be influenced by a range of factors, including variations in medical practice. In this study, we present data from a French national registry of medical practices that provide real-life insight into trends in PSA testing, management of PC, and disease-specific mortality.

Between 2006 and 2018, the study identified 692 516 men with PC and 3 899 509 control men (Supplementary material [Methods], Supplementary Table 1, and Supplementary Fig. 1). During this period, 37 640 010 PSA blood tests were performed, 1 860 156 before the diagnosis of a PC and 15 685 675 for men without PC. We found that 50% of men had received at least five PSA blood tests, but the first one was taken late in life, with a peak in the decade between 65 and 75 yr of age (Fig. 1). In the control men, the median age for first PSA testing decreased from 69 yr (interquartile range [IR]: 62–75) in 2006 to 64 yr (IR: 57–71) in 2018. The youngest median ages for the first PSA test were 59 (IR: 53–65) and 61 (IR: 54–69) yr in Martinique and Guadeloupe, respectively (Supplementary Table 2).

The proportion of PC diagnosed in the population having undergone PSA tests was 15.1% in continental regions, with a greater proportion observed in the West Indies, including Martinique (21.6%) and Guadeloupe (20.8%; Supplementary Table 3).

Of the PC cases, 28% were detected at the first PSA test. In men aged 50–70 yr, 23.3% had locally advanced or metastatic disease, and 61.2% were first treated by radical prostatectomy (RP), associated in 88% of cases with pelvic lymphadenectomy. Distribution of first-line treatment is presented by age groups and year of inclusion in Supplementary Table 4 and Supplementary Figure 2, and by administrative regions in Supplementary Figure 3. During the observed period, administration of androgen deprivation therapy (ADT) by medical or surgical castration and chemotherapy, including new hormonal therapy (CHM), increased, while active surveillance and watchful waiting (ASWW) remained stable (Fig. 2).

Among the men diagnosed with PC, 21% received a secondary line of management and 12% a third line (Supplementary Fig. 4). Salvage pelvic radiotherapy (external beam radiotherapy [EBRT]) and ADT were used, respectively, in 7.4% and 16.8% of men who received a primary RP, with the majority of treatments (55.9% and 64.8%, respectively) given within 2 yr from surgery (Supplementary Table 5). EBRT was mainly given with neoadjuvant ADT. Long-term ADT was given as first treatment in 43.4% of men, and complemented with chemotherapy in 12.6%. Of the 12.0% of men receiving ASWW initially, 25.4% received a second treatment as follows: RP (4.45%), EBRT (1.62%), and ADT (18.93%; Supplementary Table 6). The mean ages for the initiation of treatment were 65.9 (standard deviation [SD]: 6.9), 69.9 (SD: 7.5), 64.4 (SD: 6.3),




Fig. 1 – Percentage of men without PSA test according to age group and year of inclusion. PSA = prostate-specific antigen.




Fig. 2 – Distribution of first-line management of patients with prostate cancer according to the year of diagnosis. ADT = androgen deprivation therapy; ASWW = monitoring by active surveillance or watchful waiting; BT = brachytherapy; CHM = chemotherapy or new hormonal therapy (abiraterone or enzalutamide); EBRT = external beam radiotherapy; RP = radical prostatectomy.

74.4 (SD: 10.3), and 71.9 (SD: 8.4) yr for brachytherapy, EBRT, RP, ADT, and CHM, respectively.

An excess of early mortality in men with PC was observed in all age groups, including after age 80 yr (hazard ratio [HR]: 1.19; 95% confidence interval [95% CI]: 1.19–1.20, $p < 0.0001$; [Supplementary Table 7](#)). Earliest death due to PC (matched with control population in the same region) was in Bretagne (HR: 1.26; 95% CI: 1.19–1.25) and the latest in Grand Est (HR: 1.08; 95% CI: 1.06–1.10; [Supplementary Table 8](#) and [Supplementary Fig. 5](#)).

The data presented herein were obtained from national registry databases, with their known limitations [4,5]. The patterns of first-line treatment were similar to those reported in the CaPSURE cohort [6], with approximately 50% of RP cases in the 50–75-yr age group. In the CaPSURE cohort, 9% of men received ASWW, with higher mortality in these men than in those receiving radical treatment. We did not observe this mortality difference in the patients of our cohort with ASWW as first-line management (12%), but it is notable that among them, 15% of the men who were managed by watchful waiting died within 3 yr from the diagnosis of PC. This is likely due to competing morbidities and poor health, as 19% of these men were managed for another malignancy. In contrast, the patients who received true active surveillance (AS) had better survival.

In daily practice, management of PC is dictated by prognostic groups based on age, comorbidities, and features of disease aggressiveness, and comparison between treatments is therefore inappropriate and could be misleading. Our analysis suggests that ASWW remains underutilised and was stable in France while increasing in the USA in

the same period [7]. The use of radical treatments, such as RP or EBRT, remains stable, while systemic therapies, including long-term ADT and CHM, are increasing, as reported in other countries [3]. These trends suggest an increase in men presenting with metastases at diagnosis, as well as improved detection of small-volume extraprostatic disease. PSA testing continues to increase in France. The observed regional variations in age at death cannot be attributed entirely to PC mortality because of competing causes, illustrated for instance by the low life expectancy observed in the Hauts-de-France region. After adjustment for age at death in the control population, early deaths in the PC group appeared to be higher in western France than in other regions ([Supplementary Fig. 5](#)). Health care authorities and professional societies should establish clear guidelines for PSA testing and provide support to primary care physicians in order to implement the recommendations [8]. Finally, efforts should be made to increase the utilisation of AS where appropriate and reduce overtreatment with radical therapies, which can result in significant side effects and reduced quality of life.

Author contributions: Olivier Cussenot had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Cussenot, Vicaut.

Acquisition of data: Taille, Portal, Cancel-Tassin, Cussenot, Roupret, de la Taille, Ploussard, Hamdy, Mathieu.

Analysis and interpretation of data: Taille, Portal, Cussenot, Vicaut.

Drafting of the manuscript: Cussenot, Hamdy, Taille, Cancel-Tassin.

Critical revision of the manuscript for important intellectual content: Cancel-Tassin, Cussenot.

Statistical analysis: Cussenot.

Obtaining funding: Cussenot, Vicaut.

Administrative, technical, or material support: None.

Supervision: Cussenot, Vicaut.

Other: None.

Financial disclosures: Olivier Cussenot certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Dr. Guillaume Ploussard has served on advisory boards of or as a consultant for Astellas, Pfizer, Bayer, Bouchara, Ferring, Janssen, AstraZeneca, MSD, Ipsen, Takeda, Pierre Fabre, ADACAP, and Sanofi. Professor Morgan Roupret has served on advisory boards of or as a consultant for Cepheid, Roche, Janssen, Astellas, Ferring, Pfizer, MSD, and Arquer. Professor Alexandre de la Taille has served on advisory boards of or as a consultant for Astellas, Astra Zeneca, Bouchara Recordati, Ipsen, Intuitive Surgical, Janssen, and Takeda. Professor Eric Vicaut reports receiving personal fees from Eli Lilly; receiving consultancy fees from Pfizer, Sanofi, LFB, Abbott, Fresenius, Medtronic, and Hexacath; being a member of the data safety monitoring board for CERC; receiving lecture fees from Novartis; and receiving grants from Boehringer and Sanofi. Professor Olivier Cussenot reports receiving speaker honoraria from Myriad Genetics, Inc.

Funding/Support and role of the sponsor: This work was supported by grants from Association Nationale des Malades du Cancer de la Prostate (ANAMACaP) and SCOR Corporate Foundation for Science. The study funder had no role in the study design, data collection, analysis and interpretation, or writing of the report, and in the decision to submit the article for publication.

Acknowledgements: We thank the Social Committee of the French National Assembly, and Bertrand Lukacs, designer of the database.

Data sharing statement: Data are not available to other researchers.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.euo.2024.02.008>.

References

- [1] Marhold M, Kramer G, Krainer M, Le Magnen C. The prostate cancer landscape in Europe: Current challenges, future opportunities. *Cancer Lett* 2022;526:304–10.
- [2] Hamdy FC, Donovan JL, Lane JA, et al. Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. *N Engl J Med* 2023;388:1547–58.
- [3] Desai MM, Cacciamani GE, Gill K, et al. Trends in incidence of metastatic prostate cancer in the US. *JAMA Netw Open* 2022;5:e222246.
- [4] Lukacs B, Cornu JN, Aout M, et al. Management of lower urinary tract symptoms related to benign prostatic hyperplasia in real-life practice in France: a comprehensive population study. *Eur Urol* 2013;64:493–501.
- [5] Scailteux LM, Vincendeau S, Gravis G, et al. Real-world treatment patterns among French patients with metastatic castration-resistant prostate cancer under abiraterone or enzalutamide. *Clin Genitourin Cancer* 2023;21:e362–9.
- [6] Herlemann A, Cowan JE, Washington SL 3rd, et al. Long-term prostate cancer-specific mortality after prostatectomy, brachytherapy, external beam radiation therapy, hormonal therapy, or monitoring for localized prostate cancer. *Eur Urol*. In press. <https://doi.org/10.1016/j.eururo.2023.09.024>.
- [7] Cooperberg MR, Meeks W, Fang R, Gaylis FD, Catalona WJ, Makarov DV. Time trends and variation in the use of active surveillance for management of low-risk prostate cancer in the US. *JAMA Netw Open* 2023;6:e231439.
- [8] Bernal-Soriano MC, Parker LA, López-Garrigós M, et al. Do the prostate-specific antigen (PSA) tests that are ordered in clinical practice adhere to the pertinent guidelines? *J Clin Med* 2021;10:2650.